pharmaphorum October 11, 2024
Rumours that Sanofi was in discussion with private equity groups over the sale of its consumer health business Opella have been confirmed – at least partially.
The French pharma group confirmed this morning that it has entered into talks with US-based Clayton Dubilier & Rice to sell a controlling 50% stake in the unit for what has been estimated by Reuters to be in the region of €15 billion ($16.4 billion).
Previously, other private equity groups including Bain Capital, Cinven, and Advent International had been linked to a possible $20 billion sale for the entire business, which owns brands like allergy therapies Allegra and Xyzal, irritable bowel syndrome product Buscopan, painkiller Doliprane, and Pharmaton dietary supplements. And last month Bloomberg...
Today's Sponsors
Today's Sponsor